Study identifier:NIS-CKR-DUM-2009/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A multi-center, prospective, observational study to assess the effect of patient education related to CV Risk factors in type 2 diabetes mellitus
Glycemia
-
No
-
All
4045
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
This study will address the proportion of achievement patients in treatment target goal on glycemic control, hypertension and hyperlipidemia according to ADA 2008 guideline, among outpatients coming to the Korean primary care nationwide.
Location
Location
Cheiju, Republic of Korea
Location
Busan, Republic of Korea
Location
Daegu, Republic of Korea
Location
Gwangju, Republic of Korea
Location
Hongsung, Republic of Korea
Location
Seoul, Republic of Korea
Location
Sungman, Republic of Korea
Arms | Assigned Interventions |
---|---|
1 Type II DM and Hypertension and/or Hyperlipidemia | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.